Table 1. Characteristics of 4 Randomized Controlled Trials.

	GOG -0218	ICON7	OCEANS	AURELIA
Overall population Experimental arm 1 Experimental arm 2 Control arm	1873 623 625 625	1528 764 764	484 242 242	361 179 182
Age	<60 yr or 60-69 yr or >70 yr	<60 yr or 60-69 yr or >70 yr	<65 yr or ≥65 yr	<65 yr or ≥65 yr
GOG/ECOG PS	0-2	0-2	0-1	0-2
Stage/debulking	Stage III≤1 or Stage III>1 or Stage IV	Stage I-III≤1 or Stage I-III>1 or Stage IV and inoperable Stage III	Surgery at relapse or no surgery at relapse	NR
Treatment Line time to start CT platinum-free interval	First line post surgery NA	First line post surgery NA	Recurrent ovarian cancer NA 6-12 mos or >12 mos	Recurrent ovarian cancer NA 6-12 mos or >12 mos
Experimental arm treatment 1	Cycles 1-6: C AUC6, P 175 mg/mq, BV 15 mg/kg (starting in 2 cycle) q3w; Cycles 7-22: BV 15 mg/kg q3w	Cycles 1-6: C AUC5/6, P 175 mg/mq, BV 7.5 mg/kg (starting in 2 cycle) q3w; Cycles 7-18: BV 7.5 mg/kg q3w	C AUC4, Gem 1000 mg/mq, BV 15 mg/kg q3w	P 80 mg/mq days 1, 8, 15, 22 q4w, T 4 mg/mq days 1, 8, 15 q4w (or 1.25 mg/mq days 1-5 q3w), PLD 40 mg/mq day 1 q4w, BV 15 mg/kg q3w
Experimental arm treatment 2	Cycles 1-6: C AUC6, P 175 mg/mq, BV 15 mg/kg (starting in 2 cycle) q3w; Cycles 7-22; placebo q3w
Control arm treatment	Cycles 1-6: C AUC 6, P 175 mg/mq, placebo (starting in 2 cycle) q3w; Cycles 7-22; placebo q3w	Cycles 1-6: C AUC5/6, P 175 mg/mq, placebo (starting in 2 cycle) q3w; Cycles 7-18; placebo q3w	C AUC4, GEM 1000 mg/mq, placebo q3w	P 80 mg/mq days 1, 8, 15, 22 q4w, T 4 mg/mq days 1, 8, 15 q4w (or 1.25 mg/mq days 1-5 q3w), PLD 40 mg/mq day 1 q4w
Primary endpoint	PFS	PFS	PFS	PFS
Secondary endpoints	OS, QoL	OS, ORR	OS, ORR, median duration of response	OS, ORR, QoL, safety
Median follow up	17.4 mos	48.9 mos	42 mos	13 mos